+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07505186

Exploring the Safety and Effectiveness of Camrelizumab, Chemotherapy, and Ivarmacitinib Combination Before Surgery in Resectable Esophageal Squamous Cell Carcinoma

Led by Second Affiliated Hospital, Zhejiang University, School of Medicine · Updated on 2026-10-02

45

Participants Needed

1

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are exploring new treatment options for locally advanced esophageal squamous cell carcinoma, a condition where surgery alone or with additional radiotherapy and chemotherapy has shown limited success. This study evaluates the combination of camrelizumab, chemotherapy, and the JAK inhibitor Ivarmacitinib as a neoadjuvant therapy, aiming to improve patient outcomes by enhancing the immune systems ability to target cancer cells before surgery. The trial is a Phase 2, single-arm, exploratory study focusing on safety and effectiveness. The treatment involves three cycles of neoadjuvant therapy, each lasting 21 days. During the first two cycles, patients take Ivarmacitinib tablets orally at 4 mg daily, while camrelizumab and chemotherapy drugs paclitaxel albumin bound and carboplatin are administered every 3 weeks. The third cycle does not include Ivarmacitinib. Surgery to remove the tumor is scheduled 4 to 8 weeks after completing neoadjuvant therapy. Depending on the patients condition and pathology results, postoperative radiotherapy may be considered. Camrelizumab maintenance therapy can continue for up to one year. Participants will undergo various assessments including pathological evaluations one month after surgery to determine the rate of complete and major pathological responses, imaging assessments before surgery, and long-term follow-up for event-free survival up to five years. Blood and tumor samples are collected before, during, and after treatment to study immune changes. Safety is monitored through treatment-related adverse event recording. The study continues monitoring participants until disease progression, withdrawal, loss to follow-up, or death, with a total study duration extending to 2033.

CONDITIONS

Brief Title

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Research Team

Z

Zixiang Wu, M.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here